Figure 4.
Kaplan-Meier analysis of the observed time to Tloss by day 28 response category in patients with B-ALL and month 3 response category in patients with DLBCL. (A) Among patients with B-ALL, the HR for response vs no response (NR) was 1.79 (95% confidence interval [CI], 0.64-4.99). (B) Among patients with DLBCL, the HR for response vs NR was 4.19 (95% CI, 2.19-8.02). For these analyses, the first observed Tloss for a patient was considered as an event, while patients without an observed Tloss were censored at Tlast. Tloss was determined as the first available time point after Cmax when transgene levels dropped below 50 copies per μg of DNA and was considered as an event, while patients with no observed Tloss were censored at the last observation (Tlast). PD, progressive disease; PR, partial response; SD, stable disease; UNK, unknown.

Kaplan-Meier analysis of the observed time to Tloss by day 28 response category in patients with B-ALL and month 3 response category in patients with DLBCL. (A) Among patients with B-ALL, the HR for response vs no response (NR) was 1.79 (95% confidence interval [CI], 0.64-4.99). (B) Among patients with DLBCL, the HR for response vs NR was 4.19 (95% CI, 2.19-8.02). For these analyses, the first observed Tloss for a patient was considered as an event, while patients without an observed Tloss were censored at Tlast. Tloss was determined as the first available time point after Cmax when transgene levels dropped below 50 copies per μg of DNA and was considered as an event, while patients with no observed Tloss were censored at the last observation (Tlast). PD, progressive disease; PR, partial response; SD, stable disease; UNK, unknown.

or Create an Account

Close Modal
Close Modal